Haunting appearance of bcr/abl fusion gene products in a patient with therapy related leukaemia

Leuk Res. 2006 Jan;30(1):106-8. doi: 10.1016/j.leukres.2005.05.011. Epub 2005 Jul 5.

Abstract

A 81-year-old man was diagnosed as multiple myeloma and had received melphalan for 6 years. After that, he developed acute myeloid leukemia (AML) with monosomy 7 and minor bcr/abl transcripts. Fluorescence in situ hybridization identified no detectable level of bcr/abl rearrangement. During chemotherapy for AML, minor bcr/abl transcripts disappeared and instead major bcr/abl transcripts emerged. He died of pneumonia 3 months later. At that time, neither minor nor major bcr/abl transcripts were seen. These observations suggest that certain therapy related leukemia may be susceptible to generate very small clones with bcr/abl rearrangements.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Chromosomes, Human, Pair 7 / metabolism*
  • Fatal Outcome
  • Humans
  • Leukemia, Myeloid, Acute / complications
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / metabolism*
  • Male
  • Monosomy / physiopathology*
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / metabolism*
  • Neoplasms, Second Primary / complications
  • Neoplasms, Second Primary / drug therapy
  • Neoplasms, Second Primary / metabolism*
  • Pneumonia / etiology
  • Pneumonia / metabolism